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OBJECTIVE—To report the incidence of sight-threatening vascular lesions in type 2 diabetic
subjects without retinopathy after adopting a 3-year interval screening program.
RESEARCH DESIGN AND METHODS—In all, 1,691 type 2 diabetic subjects with no
detectable retinopathy in two 50° red-free fundus photographs were scheduled for follow-up
withphotography3yearslater.Ageatdiabetesdiagnosiswas60612years,andknownduration
of diabetes was 6 6 6 years. Treatment consisted of diet only (26%), oral agents (54%), and oral
agents and/or insulin (20%). Glycated hemoglobin A1c was 6.4 6 1.5%.
RESULTS—Of the 1,322 subjects available for follow-up, 73% were still without retinopathy
after 3 years, and 28% had developed mild or moderate retinopathy, but none developed severe
nonproliferative or proliferative retinopathy. Macular edema requiring laser coagulation oc-
curred in only one eye.
CONCLUSIONS—Three-year retinal screening intervals can be recommended in subjects
with mild type 2 diabetes and no retinopathy.
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S
creening programs for early detec-
tion of sight-threatening diabetic
retinopathy are highly recom-
mended, but opinions regarding optimal
screening intervals differ. In Sweden, bi-
ennial screening examinations have long
been standard for subjects without reti-
nopathy (1). Since 2006, however, Skåne
University Hospital in Malmö has used
3-year screening intervals for type 2 dia-
betic subjects without retinopathy, as
suggested by Younis et al. (2). Here, we
describe our prospective study of the
3-year incidence of sight-threatening vas-
cular lesions in that group of patients.
RESEARCH DESIGN AND
METHODS—Type 2 diabetic patients
(disease onset at age #30 years and no
insulin treatment, or onset at age .30
years) with no retinopathy documented
in a photographic screening program
were registered in a database and sched-
uled for follow-up 3 years later. A few
weeks before the date of the follow-up
v i s i t ,an o t i c er e g a r d i n gt h et i m eo ft h e
appointment was sent to the subject by
regular mail. One reminder was sent if a
person failed to keep the scheduled ap-
pointment.
Red-free digital images of one central
and one nasal 50° ﬁeld per eye were ob-
tainedbyfundusphotography.TheInter-
national Diabetic Retinopathy and
Macula Edema Severity Scales (3) were
used for grading, which was performed
by specially trained ophthalmic nurses.
Glycated hemoglobin A1c (HbA1c)a t
baseline and follow-up was analyzed by
high-performance liquid chromatogra-
phy (Varian II Hemoglobin A1c program;
BioRad, Hercules, CA), with a normal
range of 4.0–5.3%, at Skåne University
Hospital, Malmö, which is accredited by
the Swedish Board of Conﬁrmatory As-
sessment.
Statistical calculations were per-
formed using the Student t test, or the
Mann-Whitney test and the x
2 test.
The study was conducted in accor-
dance with the Helsinki Declaration and
approved by the regional ethical review
board in Lund, Sweden.
RESULTS—Age in this patient cohort
was 55 6 12 years (mean 6 SD) at diag-
nosis and 60 6 12 years at baseline. The
k n o w nd u r a t i o no fd i a b e t e sw a s66 6
years. HbA1c was 6.4 6 1.5% at baseline
and6.361.3%atfollow-up.Thepropor-
tion receiving diet treatment at follow-up
had decreased from 26 to 12% (P ,
0.001), those taking oral agents and/or
insulin treatment had increased from
74 to 88% (P , 0.001), and subjects
taking antihypertensive medication had
increased from 56 to 68% (P , 0.001).
Data were missing on patient characteris-
tics for 2–4% and on HbA1c at baseline
and at follow-up for 4 and 7%, respec-
tively.
Ofthoseexaminedatbaseline,369did
not participate in the 3-year follow-up
photography. Patient characteristics and
HbA1c levels did not differ in those with
and without follow-up data. Compliance
was high, and only 9% of the residents in
the area who were still alive ignored or re-
fused the follow-up appointment (Fig. 1).
At follow-up, 960 of 1,322 individu-
als(.70%)werestillwithoutretinopathy
in either eye, 362 had developed mild or
moderate retinopathy, and none showed
severe nonproliferative or proliferative
retinopathy. Three subjects had signs of
macular edema, two in both eyes and one
in one eye. Only one of those ﬁve eyes
required laser treatment. The magnitude
of edema in that eye had reduced visual
acuity to 0.4, but 4 months after focal la-
ser coagulation, acuity was restored to
0.7. Thus, sight-threatening retinopathy
occurred in 5 of 2,644 eyes (0.19%) but
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(0.04%).
CONCLUSIONS—Screening for dia-
betic retinopathy is highly important for
theindividualinyearsofsavedvisionand
forsocietywithrespecttocostsassociated
withblindnessandvisualimpairment(4).
Manyprogramsrecommendyearlyscreen-
ing (5–8), but the optimal interval may
differ between groups of diabetic patients.
The World Health Organization has low-
ered the limits for what are considered to
be normal reference ranges for blood and
plasma glucoselevels (9), which hasled to
the earlier diagnosis of diabetes and has
probably also lowered the risk of sight-
threatening retinopathy. This might moti-
vate extension of the screening intervals
for people with mild diabetes. If the inter-
vals are too long, however, those individ-
uals might be more prone to disregard the
examinations, ultimately resulting in
lower compliance.
In our cohort, it appeared safe to
adopt the 3-year intervals suggested by
the Liverpool group (2). The type 2 dia-
betic subjects without retinopathy had
mild diabetes; furthermore, the known
durationwasshort,andmetaboliccontrol
was good. Only one eye required focal
laser treatment for clinically signiﬁcant
macular edema. The screening program
was designed to reduce the risk of drop-
out by notifying patients of scheduled
follow-up visits well in advance and by
sending reminders if they did not keep
the appointments. Compliance was
good in this population.
Since 1993, the consensus in Sweden
has been to provide regular retinopathy
screening at least every 2 years for all
diabetic patients, and this strategy was
conﬁrmedbythe Swedish National Board
of Health and Welfare in 1995. Because
previousestimatesfortype2patientswith
diabetesindicatedalowriskofprogression
from no retinopathy to sight-threatening
retinopathy (2), in 2010, the Swedish
National Board of Health and Welfare
changed its general recommendation for
screening intervals from 2 to 3 years in
this particular group (10). The results of
thecurrentstudysupportthatadvice,but
it may be necessary to individualize the
intervals for patients with severe diabetes.
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Figure 1—Numbers of subjects and reasons for dropout.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 1319
Agardh and Tababat-Khani